MPO and ganglioneuroma: Having established that DNase I is therapeutic even after establishment of anti-MPO autoimmunity in the 20-day cell-mediated model of anti-MPO GN, we next dissected mechanisms by which DNase I reduces systemic autoimmune responses to MPO.